id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-E-0439-0003,FDA,FDA-2006-E-0439,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-12-12T05:00:00Z,2006,12,,,2026-01-08T00:50:31Z,,0,0,0900006480461ec1
FDA-2006-E-0439-0001,FDA,FDA-2006-E-0439,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-11-29T05:00:00Z,2006,11,,,2026-01-08T00:43:18Z,,0,0,0900006480461ea5
FDA-2006-E-0439-0002,FDA,FDA-2006-E-0439,Notice Regarding Associate Power of Attorney from U.S. Patent and Trademark Office to Novo Nordisk Inc.,Other,Letter(s),2006-11-29T05:00:00Z,2006,11,,,2026-01-08T00:46:32Z,,0,0,0900006480461ebf